Data / Form D filings / Corridor Pharmaceuticals, Inc.
Corridor Pharmaceuticals, Inc.: Form D filings
Corridor Pharmaceuticals, Inc., a biotechnology company in Baltimore, MD, filed 3 Form D notices with the SEC between 2009 and 2013. The latest, on January 31, 2013, reports $1.6 million sold of a $1.8 million offering to 9 investors.
Find out what Corridor Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1122 Kenilworth Drive, Suite 401, Baltimore, MD, 21204
- Phone
- (410) 616-0916
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1471665
The full lists. Form D filings in Maryland: 608 rows, $30.40, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 31, 2013 | New notice | $1,800,000 | $1,558,429 | $241,571 | 9 | Jan 18, 2013 | sec.gov |
| Jun 24, 2010 | New notice | $14,475,000 | $13,012,475 | $1,462,525 | 8 | Jun 11, 2010 | sec.gov |
| Sep 10, 2009 | New notice | $17,502,000 | $4,161,000 | $13,341,000 | 8 | Aug 28, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Leonard Patrick Gage | Director | |
| Peter Patrick Greenleaf | Director | |
| David Patrick King | Director | |
| Brian Patrick Halak | Director | |
| Anne Patrick Shiflett | Executive Officer | |
| Mark Strobeck | Executive Officer, Director |
Other biotechnology companies in Maryland that filed recently
- BlueHealer Inc. $1 · Nov 4, 2026
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
- Uvantis Therapeutics, Inc. $100,000 · Sep 23, 2026
- Gliknik Inc $15 million · Sep 17, 2026
- Georgiamune, Inc. $92.7 million · Aug 17, 2026
Every Form D from the week of Jan 28, 2013 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Corridor Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.